抽象的

A Short Note on Current and Novel Inhibitors of HIV Protease

Romica Cretu

The design, development and clinical success of HIV peptidase inhibitors represent one among the foremost outstanding achievements of molecular drugs. This review describes all 9 presently out there FDA-approved peptidase inhibitors, discusses their pharmacokinetic properties, off-target activities, side-effects, and resistance profiles. The compounds within the varied stages of clinical development are introduced, as well as alternative approaches, aiming at different purposeful domains of HIV PR. The potential of these novel compounds to open new thanks to the rational drug style of human viruses is critically assessed.